{"id":"anc-501","_chembl":{"chemblId":"CHEMBL5790832","moleculeType":null,"molecularWeight":"463.54"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:09:18.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123099,"model":"claude-sonnet-4-5-20250929"},"description":"ANC-501 is an investigational therapeutic agent being developed by Ancora Bio, Inc. (d/b/a EmbarkNeuro, Inc.) currently in Phase 2 clinical trials. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this time.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT05439603","phase":"PHASE2","title":"ANC-501 in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.","startDate":"2022-09-19","conditions":"Major Depressive Disorder","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANC-501","genericName":"ANC-501","companyName":"Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.","companyId":"ancora-bio-inc-d-b-a-embarkneuro-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}